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ABSTRACT  173 
Background: Genome-wide association studies (GWAS) have identified determinants 174 
of chronic obstructive pulmonary disease, asthma and lung function level, however 175 
none addressed decline in lung function.  176 
Aim: We conducted the first GWAS on age-related decline in forced expiratory volume 177 
in the first second (FEV1) and in its ratio to forced vital capacity (FVC) stratified a priori 178 
by asthma status.  179 
Methods: Discovery cohorts included adults of European ancestry (1441 asthmatics, 180 
2677 non-asthmatics; Epidemiological Study on the Genetics and Environment of 181 
Asthma (EGEA); Swiss Cohort Study on Air Pollution And Lung And Heart Disease In 182 
Adults (SAPALDIA); European Community Respiratory Health Survey (ECRHS)). The 183 
associations of FEV1 and FEV1/FVC decline with 2.5 million single nucleotide 184 
polymorphisms (SNPs) were estimated. Thirty loci were followed-up by in silico 185 
replication (1160 asthmatics, 10858 non-asthmatics: Atherosclerosis Risk in 186 
Communities (ARIC); Framingham Heart Study (FHS); British 1958 Birth Cohort 187 
(B58C); Dutch asthma study).  188 
Results: Main signals identified differed between asthmatics and non-asthmatics. None 189 
of the SNPs reached genome-wide significance. The association between the height 190 
related gene DLEU7 and FEV1 decline suggested for non-asthmatics in the discovery 191 
phase was replicated (discovery P=4.8x10-6; replication P=0.03) and additional 192 
sensitivity analyses point to a relation to growth. The top ranking signal, TUSC3, 193 
associated with FEV1/FVC decline in asthmatics (P=5.3x10-8) did not replicate. SNPs 194 
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previously associated with cross-sectional lung function were not prominently 195 
associated with decline.  196 
Conclusions: Genetic heterogeneity of lung function may be extensive. Our results 197 
suggest that genetic determinants of longitudinal and cross-sectional lung function differ 198 
and vary by asthma status.  199 
 200 
 201 
Key Messages: 202 
• Knowledge regarding genes with pleiotropic effects on asthma, chronic 203 
obstructive pulmonary disease as well as on lung function level and its 204 
longitudinal course is limited.  205 
• This first GWAS meta-analysis on lung function decline conducted separately in 206 
non-asthmatic and asthmatic cohort participants suggests that genetic 207 
determinants of lung function decline are different in the two groups.  208 
• The results further suggest that previously identified genetic determinants of 209 
cross-sectional lung function are not major determinants of the decline.  210 
 211 
 212 
Capsule summary:  213 
This meta-analysis provides evidence for genetic heterogeneity of lung function 214 
between asthmatics and non-asthmatics; and between cross-sectionally and 215 
longitudinally measured lung function. The study adds evidence for the role of height-216 
related genes in lung health. 217 
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Abbreviations:  224 
ARIC, Atherosclerosis Risk in Communities Study  225 
ATS, American Thoracic Society 226 
B58C,   British 1958 Birth Cohort  227 
chr, chromosome 228 
COPD, chronic obstructive pulmonary disease 229 
ECRHS, European Community Respiratory Health Survey 230 
EGEA, Genetics and Environment of Asthma 231 
FEV1, forced expiratory volume in the first second 232 
FHS, Framingham Heart Study 233 
FVC, forced vital capacity 234 
GWAS, genome-wide association studies  235 
HapMap, Haplotype Map Project 236 
Q-Q, Quantile-quantile 237 
SAPALDIA, Swiss Cohort Study on Air Pollution And Lung And Heart Disease In Adults  238 
SNP, single nucleotide polymorphism 239 
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INTRODUCTION  240 
Low lung function is a feature of both asthma and chronic obstructive pulmonary 241 
disease (COPD), with twin studies demonstrating strong heritability (0.51 to 0.77) for 242 
forced expiratory volume in the first second (FEV1)1, 2. The two respiratory diseases and 243 
lung function itself share predisposing and phenotypic features, including increased 244 
airway responsiveness and atopy as well as exogenous risk factors3, 4. Genome-wide 245 
association studies (GWAS) have identified novel genetic loci for asthma5-10, COPD11-14, 246 
and lung function15-18 and provide the opportunity to study agnostically their overlap in 247 
genetic background19. Some of the implicated genes, such as PDE4D, support a link 248 
between asthma and COPD which may be rooted in shared pathways during lung 249 
development20. However, the majority of the genes implicated in asthma or COPD 250 
GWAS analyses have not been identified as top association signals in GWAS for lung 251 
function in the general population15-18, with the exception of HHIP and FAM13A being 252 
associated with both lung function15-18 and COPD11-14. Several lines of evidence suggest 253 
that different genes influence lung function in asthmatics and in non-asthmatics. 254 
Genome-scans in family based linkage studies identified some, but overall limited 255 
overlap between chromosomal regions linked to lung function in asthmatics21, COPD 256 
patients22 and in the general population23 and it has been suggested that genetic 257 
variation may be more important for lung function in asthma after adjusting for smoking 258 
and body size differences21, 24, 25.  259 
Here, we present results from the first lung function GWAS conducted separately for 260 
asthmatics and non-asthmatics. This current study also focuses on the rate of lung 261 
function decline in adults instead of cross-sectional lung function parameters tested in 262 
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previous GWAS15-18. The discovery cohorts included two population-based studies 263 
(SAPALDIA and ECRHS) and one asthma family-based study (EGEA), all of European 264 
ancestry with highly comparable and standardized assessment of respiratory health 265 
parameters including spirometry from two time points ten years apart. These three 266 
studies had been included in the GWAS for asthma conducted by the GABRIEL 267 
consortium7. Replication cohorts included three population-based cohorts (FHS, ARIC, 268 
B58C) and one family-based asthma study (the Dutch Asthma Study).  269 
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METHODS 270 
- Discovery cohorts and study population: Three large multi-centric cohorts EGEA26, 271 
SAPALDIA27 and ECRHS28 constitute the ESE-consortium. Personal factors of 272 
relevance to lung function decline were assessed by interview and anthropometric 273 
measurements at baseline and follow-up. Participants included in discovery phase were 274 
derived from the nested asthma case/control samples (SAPALDIA and ECRHS) or from 275 
the entire study population (EGEA) subjected to genome-wide genotyping in the context 276 
of the GABRIEL asthma GWAS7. Baseline and follow-up examination were roughly 10 277 
years apart. The analysis was restricted to adult participants (age ≥18 years at the time 278 
of the baseline spirometry) with complete information on age, height and sex as well as 279 
valid lung function measure from both surveys. Cohort study protocols were in 280 
agreement with the Declaration of Helsinki and obtained ethical approval from their 281 
respective regional and/or national review boards.  282 
- Lung function assessments, asthma status and genotypes: At each visit, a minimum of 283 
two acceptable forced expiratory flows, forced vital capacity (FVC) and forced expiratory 284 
volume in the first second (FEV1) complying with American Thoracic Society criteria 285 
were obtained26-29. No bronchodilator was administered. Based on questionnaire data, 286 
asthmatics were defined as asthma self-report at any of the completed surveys and 287 
family-based studies considered additional clinical asthma criteria (see online 288 
repository).  Genotyping for discovery cohorts was centrally performed on the Illumina 289 
Human 610quad BeadChip at the Centre National de Génotypage (CNG, Evry, 290 
France)7. Imputation of genotypes based on Hapmap2 reference panel, investigation of 291 
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population stratification and quality control criteria are described in Figure EI and Table 292 
EI in the Online Repository.  293 
-Replication Cohorts: Four cohorts of European ancestry with available genome-wide 294 
data,  ARIC30, FHS15; B58C31; Dutch asthma study32 were used for replication. Subjects 295 
included in the current analysis were older than 24 years, had complete information on 296 
covariates (age, height, and sex) and valid lung function measures from at least two 297 
time-points. The lung function measurements were conducted at least ten years apart, 298 
except three years apart for ARIC (Table I). Distinct genotype data platforms and 299 
imputation software were used (Table EII, Online Repository).  300 
- Statistical analysis: Annual decline in FEV1 and FEV1/FVC was calculated as 301 
difference between follow-up and baseline spirometric measurements (mL for FEV1 and 302 
% for FEV1/FVC) divided by the duration of follow-up in years. Standardized residuals 303 
were derived from sex-specific linear regression models adjusted for age, height and 304 
study centre in asthmatics and non-asthmatics separately. Comparability between 305 
studies of standardized residuals was tested using Wilcoxon-Mann-Whitney test 306 
(P>0.94). The standardized residuals were used as dependent variable and regressed 307 
on genome-wide single nucleotide polymorphisms (SNPs) adjusted for study-specific 308 
principal components capturing population ancestry (see online supplement for details). 309 
Study-specific SNP effect estimates were combined through meta-analysis using fixed 310 
and random effects models. We used a threshold of P<5x10-8 (the Bonferroni 311 
adjustment for one million independent tests) to declare a pooled effect as genome-312 
wide significant. Selection criteria for replication loci are described in the methods 313 
section of the online repository. SNPs with suggestive evidence of association with 314 
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decline in FEV1 or FEV1/FVC were chosen for in silico replication (Table EIII, Online 315 
Repository). Study-specific regression models and meta-analyses across replication 316 
cohorts were as described for the discovery phase. Replication cohorts with spirometry 317 
data from more than two different time points modelled the lung function decline 318 
phenotype by fitting a least-squares slope using the available data (FHS, Dutch asthma 319 
study). P≤0.05 was considered as statistically significant at the replication level.  320 
The results of the main meta-analyses for the top 1000 SNPs are available in the online 321 
repository (Table EIV A to D, Online Repository). We also conducted a meta-analysis by 322 
combining non-asthmatic and asthmatic samples and tested for heterogeneity between 323 
these samples (Table EV, Online Repository). Additional sensitivity analyses were done 324 
by: a) restricting the GWAS sample to subjects aged 30 and older for FEV1 decline 325 
(Table EIV E and F, Online Repository); b) conducting GWAS analyses on percent 326 
change instead of absolute annual decline in lung function (Table EIV G to J, Online 327 
Repository); c) investigating smoking stratified joint effects for replications SNPs (Table 328 
EVI, Online Repository); d) excluding ARIC, a cohort having substantially shorter follow-329 
up time that the other cohorts (three years instead of ten years) from replication 330 
analyses (Table EVII, Online Repository). Methods and results of these additional 331 
analyses are described in the online repository. 332 
 333 
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RESULTS 334 
Characteristics of the study populations 335 
The cohorts included in this study differed by age and type of recruitment, and 336 
accordingly in lung function and the proportion of subjects with FEV1/FVC below 70% 337 
(Table I, Table EVIII, Online Repository). Baseline lung function parameters, but not 338 
their annual changes were lower in asthmatics when compared to non-asthmatics in 339 
each study. The proportion of never smokers was comparable among asthmatics, but 340 
varied among non-asthmatics (ranging from 28.5% in B58C to 46.5% in EGEA). No 341 
substantial differences in the smoking prevalence between people with and without 342 
asthma were observed within each study. Comparing the discovery cohorts in more 343 
detail (Table EVIII, Online Repository), atopy (total IgE ≥100kU/ml) and hay fever were 344 
more prevalent in both asthmatics and non-asthmatics from EGEA when compared to 345 
ECRHS and SAPALDIA. Current asthma was more prevalent (84.4%) in EGEA than in 346 
SAPALDIA (25.5%) or ECRHS (43.3%) and the prevalence of a positive family history 347 
for asthma was also highest in EGEA, in agreement with the study design. Asthmatics 348 
from EGEA had a younger age of disease onset due to the mode of recruitment of the 349 
proband.  350 
 351 
Main findings from meta-analyses of discovery and replication phase  352 
In the discovery phase, GWAS meta-analysis of decline in FEV1 and FEV1/FVC was 353 
conducted in 2677 non-asthmatics and in 1441 asthmatics. Genomic inflation factors 354 
were low for both lung function parameters (λ<1.047, Table EIX, Online Repository) 355 
suggesting minimal unaccounted population stratification. The replication panel included 356 
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a total of 10’858 non-asthmatics and 1’138 asthmatics. Thirty lead SNPs belonging to 357 
30 loci (5x10-8< Pdiscovery <6x10-5) were chosen for replication.  358 
The four lung function parameter- and asthma-specific meta-analyses identified one 359 
association signal that almost reached the genome-wide significance level (P = 5.3x10-360 
8) at the locus 8p22 containing the TUSC3 gene for FEV1/FVC decline in asthmatics 361 
while all other signals had P<5x10-7 (Figure I), but this signal was not associated with 362 
FEV1/FVC decline in asthmatics in the replication sample. The only locus of the 363 
selected replication candidate loci that formally replicated was 13q14.3, containing the 364 
DLEU7 gene, associated with decline in FEV1 in the non-asthmatics (Pdiscovery=4.8x10-6 365 
and  Preplication=0.03).  366 
In the global post hoc analysis combining both asthmatics and non-asthmatics 367 
(N=4118), a striking finding was the absence of any pronounced association signals (P 368 
>1x10-6) despite increased statistical power. This was in agreement with the minimal 369 
overlap of association signals observed in asthmatics and non-asthmatics separately. 370 
Most signals at P<10-5 from the asthma-stratified analysis in the discovery phase 371 
exhibited statistically significant heterogeneity of effects between the two groups (Table 372 
II). At the replication stage, none of the replication SNPs was associated with lung 373 
function decline in asthmatics and non-asthmatics combined. 374 
 375 
Association signals for annual decline in FEV1 in non-asthmatics 376 
Of fifteen SNPs associated at P<10-5 with decline in FEV1 in non-asthmatics ten were 377 
clustered at position 112.3 Mb on chromosome 9, containing genes TXN, MUSK and 378 
SVEP1. Two of the 15 SNPs were located at 13q14.3 in a locus containing the DLEU7 379 
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gene; three SNPs belonged to three distinct loci. The association of lead and proxy 380 
SNPs in DLEU7 (Figure II), but not TXN/MUSK/SVEP1 (Figure EII) or the other SNPs 381 
(Table II) replicated. The G-allele of SNP rs9316500 near the DLEU7 gene was 382 
positively associated with annual FEV1 decline in the discovery cohorts (P=4.8x10-6) 383 
and in the replication cohorts (P=0.026). Although heterogeneity between studies was 384 
not significant (P=0.61), the combined P value did not reach the genome-wide level 385 
(P=5.7x10-5).  386 
 387 
Association signals for annual decline in FEV1 in asthmatics  388 
Eighteen SNPs in nine distinct chromosomal locations were associated with decline in 389 
FEV1 in asthmatics at P<10-5. None of the loci selected for in silico replication was 390 
confirmed (Table II).  391 
 392 
Association signals for annual decline in FEV1/FVC in non-asthmatics  393 
Seven loci showed association with FEV1/FVC decline in non-asthmatics at 10-6<P<10-394 
5
, but no locus selected for replication was confirmed (Table II).  395 
 396 
Association signals for annual decline in FEV1/FVC in asthmatics 397 
Twelve SNPs at the locus 8p22 containing the gene TUSC3 at 15.68Mb were 398 
associated with FEV1/FVC decline at P<10-7 in asthmatics (Figure I). Regional locus 399 
plot and forest plot are presented in the online repository (Figure EIII). The top 400 
association signals in this locus were conferred by distinct SNPs in each cohort, though 401 
apparently they were located in the same putative haplotype segment in SAPALDIA and 402 
Imboden et al. 20 
 
 
in EGEA (Figure EIV, Online Repository). There was no statistically significant 403 
association in ECRHS. Meta-analysis of the discovery samples identified SNP 404 
rs4831760 as top signal in TUSC3 gene, but heterogeneity between discovery studies 405 
was borderline significant (P=0.07). The C-allele (P=5.3x10-8) was positively associated 406 
with annual decline in FEV1/FVC in asthmatics (Beta=0.22 ±0.04 (standard error); Table 407 
II). However this association was not replicated (P=0.80). In the meta-analysis 408 
combining discovery and replication samples the resulting P-value for rs4831760 was 409 
2.8x10-5. All but the Dutch asthma study, exhibited effect estimates in the same 410 
direction as the discovery panel. Two other candidate loci (MPP7 and SYNE2) also 411 
failed replication testing. 412 
   413 
SNPs previously associated in GWAS meta-analyses on cross-sectional lung function  414 
The associations of top hit SNPs from previous GWAS meta-analyses on cross-415 
sectional lung function11, 15-18 and a replication study in asthmatics33 were assessed 416 
separately for asthmatics and non-asthmatics in the discovery cohorts. Associations 417 
were assessed for both, lung function parameters of decline (annual decline and 418 
percent change) and cross-sectional lung function level. Overall, a subset of variants 419 
and loci showed replication of association with cross-sectional lung function in either 420 
non-asthmatics or asthmatics. Few of the loci showed strong association with decline in 421 
lung function. We present associations at P<0.05 in Table III and those at P≥0.05 in 422 
Table EX in the online repository. 423 
For baseline FEV1, we observed associations for SNPs belonging to 4q24 (GSTCD, 424 
rs11731417, P=1.3x10-4) and 15q23 (THSD4, rs1913768, P=0.003). Associations with 425 
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baseline FEV1 were mainly restricted to non-asthmatics. For baseline FEV1/FVC, 426 
associations of SNPs of THSD4 were prominent (e.g. rs12899618, P=3.3x10-4) and 427 
again restricted to non-asthmatics.  428 
For decline phenotypes of FEV1, we observed associations for SNPs in regions 6p21 429 
(DAAM2, 0.003<P<0.02) and 4q28 (HHIP, 0.02<P<0.05) among asthmatics and in 430 
THSD4 (0.003<P<0.04) among non-asthmatics. The strongest associations observed 431 
for decline phenotypes of FEV1/FVC were two SNPs in MMP15 (16q13, 432 
0.003<P<0.002) in non-asthmatics, only. Association in the combined sample of 433 
asthmatics and non-asthmatics did not substantially alter the results. 434 
 435 
Summary of findings from sensitivity analyses  436 
We observed in non-asthmatics, aged 30 years and more, that MUSK and DLEU7 were 437 
no longer prominently associated with FEV1 decline, but SNPs in other genes remained 438 
strongly associated (ZIC1, rs6785065, P=2.3x10-5; UBL3, rs278037, P=4.8x10-5). 439 
Results of the GWAS on percent change in lung function showed that the FEV1 440 
association signal for DLEU7 in the non-asthmatics was no longer significant; however 441 
the signals for MUSK (rs1889321, P=2.92x10-7) and other loci remained unaltered 442 
(ZIC1, rs6785065, P=2.0x10-5; KIRREL3, rs11604082, P=4.1x10-6; KIAA2117, 443 
rs10082549, P=2.7x10-6). Top signals associated with decline in FEV1/FVC in 444 
asthmatics remained unaltered for TUSC3 (rs4831760, P=5.2x10-8) and for SYNE2 445 
(rs7144584, P=6.4x10-7) after taking baseline lung function into account. 446 
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Smoking stratified analyses of the replication SNPs revealed no substantial difference in 447 
association between ever and never smokers except for a few SNPs belonging to loci 448 
containing SYNE2, RORA, BCAS1, or PLXNA4 genes.  449 
Replication meta-analysis excluding the ARIC data substantially reduced sample size in 450 
non-asthmatics and the association of DLEU7 with decline of FEV1 was no longer 451 
significant. Instead two loci for association with decline in FEV1 in asthmatics (PLXNA4, 452 
rs10808265, Pdiscovery=1.7x10-6, Preplication=0.02 and SLC45A3, rs16856186, 453 
Pdiscovery=8.9x10-6, Preplication=0.04) and one locus, FLJ25393, for decline in FEV1/FVC in 454 
non-asthmatics (rs2658782, Pdiscovery=4.3x10-6, Preplication=0.03) gained statistical 455 
significance.  456 
 457 
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DISCUSSION 458 
A main result of this study is the observed genetic heterogeneity of lung function decline 459 
between asthmatics and non-asthmatics. When we combined the two groups in the 460 
discovery phase we observed no genome-wide significant association signal despite 461 
larger sample size. All top hit association signals detected by the asthma stratified 462 
analysis showed significant heterogeneity according to the disease status. In the 463 
replication phase, this heterogeneity was also confirmed for the DLEU7 locus which was 464 
associated with FEV1 decline in non-asthmatics only. Finally, many of the SNPs 465 
identified by previous GWAS on lung function exhibited associations specific to asthma 466 
status. 467 
 468 
The finding of genetic heterogeneity in lung function reported here is consistent with 469 
available evidence. Differences in familial segregation of FEV1 in asthmatic and non-470 
asthmatic families previously suggested genetic heterogeneity between these two 471 
groups24. Agnostic studies investigating genetic determinants of lung function in both, 472 
family-based 21, 22, 34-37 and population-based samples15-18, 23, 25 produced little overlap in 473 
chromosomal regions. Genome-wide scans on lung function in asthma21, 38 or COPD22 474 
families also suggested a heterogeneous genetic architecture of lung function. 475 
 476 
Nevertheless, some previously reported overlapping linkage regions for the ratio of 477 
FEV1 over vital capacity (FEV1/VC) and FEV1 over the forced vital capacity 478 
(FEV1/FVC) in families with asthma and COPD21, 22 suggest that at least some gene(s) 479 
could be important in the development of airway obstruction in both diseases. 480 
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Furthermore, genetic polymorphisms in glutathione S-transferases39-42 as well as 481 
ADAM-3343-46 were associated with lower lung function at all ages and in different 482 
subgroups of the population (general population, patients with COPD and asthma). 483 
Gene-lung function associations that are of relevance to several population and patient 484 
strata may be determined specifically by complex gene-gene and gene-environment 485 
interactions, as suggested for lung function decline and its complex association with 486 
estrogen receptor 1 polymorphisms, smoking, steroid use, and gender32, 47. While 487 
ignored in ours as well as previous GWAS, such effect modifications should be 488 
considered in the future48.  489 
 490 
Results from the Busselton Health Study on familial aggregation and heritability of adult 491 
lung function previously suggested the existence of genetic determinants of adult lung 492 
function independent of asthma, atopy, cigarette smoking, height, age or sex25. 493 
Consistent with these results, neither asthma, atopy and COPD genes previously 494 
identified in large GWAS5-9, 11 nor genes related to smoking behavior49  were associated 495 
with lung function decline in our study. The association of FEV1 decline with a gene 496 
related to height, DLEU7, was ranking high, but only in subjects without asthma 497 
(rs9316500, Pdiscovery=4.8x 10-6; Preplication=0.03). DLEU7 gene product and expression 498 
remain poorly characterized, but its mRNA has been detected in the lung. The DLEU7 499 
locus was identified as a determinant of adult height in previous GWAS meta-500 
analyses50-52. Three other height genes, HHIP, GPR126 and PTCH, were associated 501 
with cross-sectional lung function15-17. All of these lung function models including ours 502 
were adjusted for adult height. The observed association, related to both HHIP and 503 
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DLEU7 being associated with peak height velocity in infancy51, suggests that aspects 504 
beyond adult height influence lung function and possibly its response to non-genetic 505 
determinants. Several genes implicated in respiratory diseases indicate that early lung 506 
development impacts respiratory health later in life20. Sensitivity analyses are supportive 507 
for a growth-specific role of DLEU7. The association of genetic variants in DLEU7 with 508 
decline in FEV1 disappeared in analyses considering baseline lung function or restricted 509 
to subjects above age 30 with no remaining physiologic lung growth. There might be a 510 
link between physiologic growth and unregulated cell differentiation as the DLEU7 gene 511 
is also a proposed tumor suppressor gene in chronic lymphocytic leukemia53-55. 512 
Evidence emerges for a role of DLEU7 in counterbalancing the proliferative impact of 513 
NF-kB on various cell types56. The potential role of the gene product of TUSC3, a 514 
proposed tumor suppressor gene57, in lung physiology is discussed in the Online 515 
Repository.  516 
None of the SNPs identified in GWAS of cross-sectional lung function15-18 ranked high in 517 
this current GWAS on lung function decline. A strong risk factor for accelerated lung 518 
function decline in adulthood is cigarette smoking, but our study was too small to assess 519 
gene smoking interaction at the GWAS level. We had decided a priori against smoking 520 
adjustment as it is not a confounder, and any link between genotype and smoking is 521 
likely to be, at least in part, in the same causal pathway (e.g. gene products 522 
metabolizing tobacco constituents or influencing smoking behavior). Their identification 523 
as determinants of lung function decline is of public health importance. Consistent with 524 
previous GWAS on cross-sectional lung function15-18, neither the TUSC3 (heterogeneity 525 
between ever/never smokers P=0.98) nor other top hit signals were modified by 526 
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smoking except for SNPs in SYNE2, RORA, BCAS1 and PLXN4. Arguments for 527 
biologic plausibility are mentioned in the Online Repository. 528 
The strength of the present study is the longitudinal design of all cohorts included. 529 
Repeated spirometric assessments within the same subject is thought to capture more 530 
precisely exogenous factors and genes leading to accelerated loss of lung function in 531 
adulthood58. The discovery cohorts shared comparable questionnaire and spirometry 532 
protocols and they were specifically designed to investigate environmental and genetic 533 
causes of lung function decline and asthma in a standardized way. Each study has two 534 
measures of pre-bronchodilator lung function about ten years apart, but clearly our 535 
findings would be more robust if further lung function measures were available over an 536 
even longer period of follow-up. All discovery cohorts have used the same genotyping 537 
platform and stringent quality control criteria have been applied.  538 
Sample size is a limitation of this study, and remains a general challenge in lung 539 
function studies with a need for high phenotypic comparability as spirometry results are 540 
sensitive to technicians and devices used59. The pre-bronchodilation lung function 541 
measurements in our and previous lung function GWAS do not allow to differentiate 542 
reversible from non-reversible obstruction to airflow. Populations included in this study 543 
differed by age which is also reflected by the diverging proportion of subjects with 544 
FEV1/FVC <0.7 at follow-up between the discovery cohorts. Discovery and replication 545 
populations also differ by time spacing between the spirometry assessments. We can 546 
only speculate of on the overall impact of such differences. We do note that replication 547 
results were sensitive to the exclusion of ARIC data (the study with highest mean age, 548 
largest annual decline, and shortest follow-up time). 549 
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Other limitations are shared with any GWAS meta-analyses investigating complex 550 
phenotypes such as lack in power for investigating gene-environment interactions or 551 
studying subgroups of diseases. As the sample size of our study was comparatively 552 
small, especially for the asthmatic sample in the replication phase, we had limited ability 553 
to address differences in asthma sub-phenotypes or the impact of asthma medication 554 
intake. It is also likely that a substantial part of complex disease may be explained by 555 
rare mutations not considered by current GWAS. Finally, assessing the joint effect of 556 
SNPs having small effects individually and potentially interacting with each other 557 
remains another challenge. 558 
 559 
In conclusion, this first GWAS meta-analysis on lung function decline provides 560 
suggestive evidence for genetic heterogeneity between persons with and without 561 
asthma and between cross-sectionally and longitudinally measured lung function. 562 
Consistent with cross-sectional GWAS, our results are also suggestive of height related 563 
genes playing a role. Further studies in this area would be enhanced by greater 564 
comparability of age range, spacing of lung function assessments, and asthma sub-565 
phenotypes (including treatment) to decrease phenotypic heterogeneity and therefore 566 
increase statistical power to detect true association candidate loci60.  567 
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 818 
FIGURE LEGENDS: 819 
Figure I: Manhattan plots of association results for decline in lung function. A) FEV1 820 
decline in non-asthmatics. B) FEV1 decline in asthmatics. C) FEV1/FVC decline in non-821 
asthmatics. D) FEV1/FVC decline in asthmatics. 822 
 823 
Figure II: Association of the DLEU7 locus with decline in FEV1 in non-asthmatics. A) 824 
Regional association plot, discovery phase. B) Forest plot for rs9316500. A: 825 
Chromosome position (NCBI build 36.3) and recombination rate (hg18 build). The 826 
sentinel SNP is represented as a diamond and r2 for SNPs to the sentinel SNP 827 
(HapMap CEU phase II). B: The size of the square of each study reflects the 828 
contributing weight to the meta-analysis, details in Table EXI.  829 
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FOOTNOTES 831 
Footnotes to Table I: 832 
* N comprises the maximal number of subjects who contributed to at least one GWAS 833 
analysis (either decline in FEV1 or in FEV1/FVC). 834 
†Time spacing between the first and the second spirometry assessment. 835 
 836 
Footnote to Table II: 837 
* MUSK refers to TXN/MUSK/SVEP1 locus. 838 
 839 
Footnote to Table III: 840 
* Associations of SNPs previously associated in cross-sectional lung function in GWAS 841 
studies, (1) Framingham 15, (2) CHARGE 17, (3) Spirometa 16, (4) Asthmatics33 and (5) 842 
CHARGE-Spirometa18 were assessed in the discovery cohorts only if minor allele 843 
frequency (MAF) was at least 5%. SNPs tested for associations: ADAM19: rs2277027, 844 
rs1422795, rs6890282; ADCY2: rs7710510, rs6555465; ARMC2: rs2798641; C10orf11: 845 
rs11001819; CCDC38: rs1036429; CDC123: rs7068966; CFDP1: rs2865531; DAAM2: 846 
rs3008798, rs1318002, rs2395730; FAM13A1: rs6830970, rs2869967; GPR126: 847 
rs9496346, rs6570507, rs11155242, rs7753012, rs3748069, rs171891, rs263178; 848 
HDAC4: rs12477314; HHIP: rs1032295, rs1512285, rs720485, rs1828591, rs13118928, 849 
rs1512288, rs6817273; HTR4: rs3995090, rs1833710; INTS12-GSTCD-NPNT: 850 
rs3960769, rs17035917, rs17035960, rs11727735, rs10516526, rs11731417; KCEN2: 851 
rs9978142; LRP1: rs11172113; MECOM: rs1344555; MFAP2: rs2284746; MMP15: 852 
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rs2304488, rs12447804; MTMR3: rs17646919; NCR3: rs2857595; NOTCH4: rs206015; 853 
ONECUT1: rs2456526; PID1: rs1435867, rs1358443, rs3845823; PTCH1: rs10512249, 854 
rs576594; RARB: rs1529672; SPATA9: rs153916; TGFB2: rs993925; THSD4: 855 
rs12899618; THSD4: rs1568010, rs1913768; TNS1: rs918949, rs1035672, rs929937; 856 
ZKSCAN3: rs6903823. Non-significant associations reported in online repository. 857 
† Baseline cross-sectional lung function was calculated using Quanjer formula61.  858 
‡Proxies tested for cross-sectional association (r2, D’): for rs12447804 - rs2304488 859 
(0.87, 1); for rs12477314 - rs4521068 (1, 1); for rs2865531 - rs12917651 (1, 1). 860 
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TABLES 
Table I: Baseline characteristics of discovery and replication cohorts, by asthma status.  
     % mean ± SD mean ± SD mean ± SD (L) mean ± SD 
mean ± SD 
(y) 
mean ± SD 
(mL/y) 
mean ± SD 
(%/y) %  
Non-asthmatics 
 
 N* 
 
Men 
 
Age  
 
Height  
 
FEV1  
 
FEV1/FVC 
 
Follow-up 
length† 
 
annual decline 
FEV1 
 
annual 
decline 
FEV1/FVC 
 
Never 
smokers 
 
Discovery (ESE-cohorts)                  
EGEA 529 45.2 41.4 ±11.7 1.68 ±0.08 3.45 ±0.78 0.83 ±0.06 11.2 ±1.0 -28.6 ±25.7 -0.47 ±0.53 46.5 
SAPALDIA 805 49.2 41.8 ±11.1 1.70 ±0.09 3.62 ±0.81 0.79 ± 0.07 10.9 ±0.2 -34.0 ± 28.3  -0.40  ±0.46 43.1 
ECRHS 1343 49.7 34.1  ±7.1 1.70 ±0.10 3.81 ±0.83 0.83 ±0.06 8.9 ±0.9 -26.3 ±30.7 -0.30 ±0.50 40.7 
Replication with in silico data                  
ARIC 7156  46.3  54.5 ±5.6  1.69 ±0.09  3.01 ±0.75  0.75 ±0.07  2.9 ±0.2 -52.0 ±57.4 -0.19 ±0.98 40.8 
FHS  3232 44.9  52.9 ±10.2  1.67 ±0.10  2.89 ±0.81  0.77 ±0.08  10.5 ±3.6 -24.9 ±23.9 -0.33 ±0.57 36.1 
B58C 470  48.7 35.0 ±0.2 1.70 ±0.09 3.68 ±0.73 0.81 ±0.06 10.1 ±0.5 -34.9 ±31.4 -0.21 ±0.67 28.5 
            
Asthmatics           
            
Discovery (ESE-cohorts)                 
EGEA 330 50.6 38.5 ± 12.5 1.70  ±0.09 3.26 ±0.91 0.77  ±0.11 11.6 ± 1.0 -27.6 ±39.4 -0.44 ±0.68 44.6 
SAPALDIA 540 46.5 40.2 ± 11.3 1.69  ±0.09 3.36 ±0.89  0.76 ±0.95 10.9 ± 0.3  -35.5 ±33.9 -0.45  ±0.54 42.4 
ECRHS 571 42.7 33.9 ±7.3 1.69  ±0.10 3.43 ±0.81 0.78  ±0.09 8.8 ±0.7 -26.7 ±42.6 -0.20 ±0.60 42.5 
Replication with in silico data                  
ARIC 325  50.2  54.2 ±5.7 1.69 ±0.10  2.73 ±0.87  0.68 ±0.10  2.9 ±0.2 -43.9 ±77.2 -0.037 ±1.25 41.9 
FHS  346 41.3  50.1 ±10.3 1.68  ±0.09  2.72 ±0.84  0.73 ±0.09  10.2 ±3.8 -29.8 ±23.7 -0.38 ±0.51 36.1 
B58C 231 44.2 35.0 ±0.2 1.69  ±0.10 3.45 ±0.75 0.78 ±0.08 10.3 ±0.5 -34.4 ±37.6 -0.17 ±0.89 37.2 
Dutch Asthma 258 60.9 35.1 ±7.6 1.75 ±0.09 3.03 ±0.95 0.65 ±0.13 14.6 ±7.2 -22.8 ±47.0 -0.14 ±0.89 40.7 
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Table II: Association of (lead) SNPs subjected to replication with A) decline in FEV1 and B) decline in FEV1/FVC; stratified by asthma 
status. 
A - decline in FEV1 Discovery phase Replication phase 
dbSNP ID chr 
position    
(build 36.3) 
gene 
nearby 
Maximal 
frequency 
of coding 
allele 
Estimate 
of joint 
analysis  
P for joint 
analysis  
P for 
heterogeneity 
between 
studies 
P for 
heterogeneity 
between 
asthmatics and 
non-
asthmatics 
Estimate of 
joint 
analysis in 
replication 
cohorts 
P for joint 
analysis  
P for 
heterogeneity 
between  
between 
studies 
P for 
heterogeneity 
between 
asthmatics and 
non-asthmatics 
Non-Asthmatics                  
rs1889321 9 112340656 MUSK* 0.287 -0.150 6.95E-07 0.814 0.0187 -0.011 0.480 0.713 0.053 
rs9316500 13 49992115 DLEU7 0.336 0.135 4.81E-06 0.613 0.0255 0.033 0.026 0.124 0.075 
rs6785065 3 149016533 ZIC1 0.274 -0.136 0.00001 0.234 0.1700 -0.006 0.686 0.525 0.55 
rs278037 13 29322627 UBL3 0.178 -0.151 0.00002 0.364 0.0058 -0.006 0.734 0.231 0.50 
rs7641198 3 117396577 LSAMP 0.147 0.164 0.00003 0.669 0.1997 -0.002 0.939 0.690 0.15 
rs421847 21 19269950 PRSS7 0.281 0.128 0.00003 0.831 0.0350 -0.016 0.310 0.247 0.86 
rs496809 18 74857661 SALL3 0.078 -0.236 0.00004 0.412 0.0041 0.022 0.443 0.373 0.60 
rs10933964 3 110021881 TRAT1 0.499 -0.117 0.00006 0.345 0.0022 -0.015 0.265 0.869 0.041 
Asthmatics                  
rs10808265 7 131840229 PLXNA4B 0.484 -0.175 1.66E-06 0.844 0.0020 0.069 0.105 0.258 0.16 
rs1902618 15 58951491 RORA 0.234 -0.220 1.72E-06 0.449 0.0043 0.029 0.590 0.777 0.58 
rs3843306 1 91060718 BARHL2 0.460 0.176 5.11E-06 0.042 8.33E-06 0.047 0.270 0.883 0.24 
rs7006290 8 41734295 ANK1 0.319 0.185 5.19E-06 0.058 0.0003 0.038 0.456 0.574 0.45 
rs12436689 14 84723772 FLRT2 0.244 -0.212 6.87E-06 0.420 0.0010 -0.017 0.759 0.051 0.95 
rs12615721 2 81710037 CTNNA2 0.104 -0.303 7.65E-06 0.853 0.0020 -0.127 0.129 0.824 0.08 
rs10516809 4 89640109 HERC5 0.101 0.306 8.67E-06 0.790 3.60E-05 -0.060 0.446 0.200 0.41 
rs16856186 1 203944749 SLC45A3 0.098 0.268 8.92E-06 0.510 0.0034 -0.079 0.350 0.094 0.46 
rs158536 20 52148709 BCAS1 0.408 0.162 0.00002 0.948 0.0001 0.075 0.100 0.917 0.09 
rs477725 19 42066106 ZNF345 0.158 0.223 0.00003 0.821 0.0031 -0.069 0.273 0.255 0.14 
rs9662589 1 230344234 DISC1 0.221 0.188 0.00005 0.868 0.0002 -0.020 0.706 0.153 0.76 
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rs777433 2 128084705 LIMS2 0.407 0.151 0.00010 0.811 0.1223 -0.018 0.691 0.564 0.52 
                          
B - decline in FEV1/FVC 
 
Discovery phase Replication phase 
dbSNP ID chr 
position    
(build 36.3) 
gene    
nearby 
Maximal 
frequency 
of coding 
allele 
Estimate 
of joint 
analysis  
P for joint 
analysis  
P for 
heterogeneity 
between 
studies 
P for 
heterogeneity 
between 
asthmatics and 
non-
asthmatics 
estimate of 
joint 
analysis in 
replication 
cohorts 
P for joint 
analysis  
P for 
heterogeneity 
between  
between 
studies 
 P for 
heterogeneity 
between 
asthmatics and 
non-asthmatics 
Non-Asthmatics                  
rs2658782 11 92806379 FLJ25393 0.166 0.186 4.33E-06 0.362 0.0041 0.031 0.135 0.242 0.91 
rs1867982 10 73197053 C10orf54 0.109 0.202 5.56E-06 0.839 0.0034 -0.008 0.745 0.412 0.24 
rs12712969 2 46185673 PRKCE 0.268 -0.147 7.08E-06 0.687 0.0116 0.012 0.448 0.916 0.76 
rs10187654 2 234478798 TRPM8 0.205 0.151 8.87E-06 0.797 0.0049 -0.015 0.382 0.676 0.15 
rs356642 2 100903870 NPAS2 0.189 0.158 9.79E-06 0.162 0.0014 -0.010 0.565 0.282 0.28 
rs890515 8 67534388 ADHFE1 0.497 0.119 0.00001 0.580 0.0257 0.003 0.847 0.443 0.58 
rs10738890 9 32448081 DDX58 0.391 -0.118 0.00003 0.832 0.5847 -0.009 0.567 0.032 0.73 
Asthmatics                  
rs4831760 8 15576956 TUSC3 0.326 0.222 5.27E-08 0.066 7.74E-08 0.011 0.799 0.541 0.73 
rs7144584 14 63345565 SYNE2 0.116 -0.318 5.62E-07 0.616 0.0010 0.089 0.272 0.752 0.43 
rs1148186 10 28657641 MPP7 0.194 0.219 7.28E-06 0.760 0.0035 -0.033 0.602 0.967 0.60 
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Table III : Association* of SNPs previously identified in GWAS on cross-sectional lung function with percent predicted lung function at 
baseline, as well as percent change and annual decline in lung function for A) FEV1 and B) FEV1/FVC in ESE-discovery cohorts by 
asthma status. 
 
            
Non-Asthmatics 
  
Asthmatics 
  
A           
FEV1 percent 
predicted 
FEV1 percent 
change 
FEV1 
decline [%/y] 
FEV1 percent 
predicted 
FEV1 percent 
change 
FEV1 decline 
[%/y] 
dbSNP ID chr 
position    
(build 36.3) refs gene nearby 
Maximal 
frequency of 
coding allele P-value P-value P-value P-value P-value P-value 
rs1435867 2 229219173 2 PID1 0.065 0.021 0.845 0.418 0.824 0.321 0.377 
rs17035917 4 106740191 2,3 INTS12-GSTCD-NPNT 0.071 0.006 0.135 0.077 0.073 0.056 0.061 
rs17035960 4 106751295 2,3 INTS12-GSTCD-NPNT 0.071 0.004 0.093 0.054 0.067 0.056 0.063 
rs11727735 4 106851319 2,3 INTS12-GSTCD-NPNT 0.076 2.14E-04 0.361 0.198 0.057 0.114 0.074 
rs10516526 4 106908353 2,3 INTS12-GSTCD-NPNT 0.072 1.96E-04 0.327 0.177 0.062 0.120 0.078 
rs11731417 4 106965461 2,3 INTS12-GSTCD-NPNT 0.073 1.32E-04 0.335 0.177 0.048 0.146 0.090 
rs1032295 4 145654034 2 HHIP 0.397 0.173 0.096 0.306 0.274 0.042 0.033 
rs1512285 4 145670409   HHIP 0.462 0.032 0.029 0.141 0.152 0.033 0.024 
rs720485 4 145682038 2,3 HHIP 0.391 0.159 0.510 0.786 0.943 0.044 0.058 
rs1512288 4 145710731 2,3 HHIP 0.401 0.188 0.533 0.813 0.781 0.046 0.057 
rs6817273 4 145711453 2,3 HHIP 0.400 0.179 0.535 0.816 0.866 0.046 0.057 
rs3008798 6 39887840 3 DAAM2 0.464 0.326 0.960 0.850 0.755 0.009 0.017 
rs1318002 6 39892112 3 DAAM2 0.480 0.649 0.725 0.902 0.782 0.015 0.023 
rs2395730 6 39892343 3 DAAM2 0.442 0.522 0.716 0.513 0.619 0.003 0.007 
rs12899618 15 69432174 3 THSD4 0.158 0.003 0.003 0.014 0.424 0.137 0.131 
rs1913768 15 69436598 3 THSD4 0.159 0.003 0.002 0.011 0.393 0.162 0.152 
rs1568010 15 69455566 4 THSD4 0.372 0.535 0.042 0.067 0.413 0.241 0.111 
rs2304488 16 56631711 1 MMP15 0.186 0.033 0.101 0.147 0.112 0.344 0.506 
rs12447804‡ 16 56632783 5 MMP15 0.179 0.033 0.111 0.161 0.112 0.382 0.482 
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Non-Asthmatics 
  
Asthmatics  
  
B           
FEV1 percent 
predicted 
FEV1 percent 
change 
FEV1 
decline [%/y] 
FEV1 percent 
predicted 
FEV1 percent 
change 
FEV1 decline 
[%/y] 
dbSNP ID chr 
position    
(build 36.3) refs gene nearby 
Maximal 
frequency of 
coding allele P-value P-value P-value P-value P-value P-value 
rs918949 2 218382942 2,3 TNS1 0.384 0.010 0.133 0.089 0.076 0.241 0.256 
rs1035672 2 218383444 2,3 TNS1 0.384 0.010 0.133 0.089 0.093 0.243 0.258 
rs929937 2 218417460 2,4 TNS1 0.386 0.623 0.017 0.016 0.004 0.915 0.888 
rs3845823 2 229611365 4 PID1 0.432 0.039 0.963 0.852 0.393 0.997 0.987 
rs12477314‡ 2 239542085 5 HDAC4 0.215 0.023 0.727 0.655 0.125 0.361 0.278 
rs1529672 3 25495586 5 RARB 0.159 0.012 0.329 0.337 0.605 0.716 0.860 
rs1828591 4 145700230 2,3 HHIP 0.394 0.031 0.470 0.345 0.254 0.138 0.139 
rs13118928 4 145705839 2,3 HHIP 0.393 0.043 0.500 0.371 0.271 0.132 0.132 
rs3995090 5 147826008 2,3 HTR4 0.394 0.011 0.785 0.699 0.029 0.649 0.456 
rs2395730 6 39892343 3 DAAM2 0.442 0.277 0.554 0.685 0.979 0.036 0.039 
rs2798641 6 109374743 5 ARMC2 0.209 0.315 0.444 0.530 0.006 0.188 0.158 
rs9496346 6 142711031 2 GPR126 0.316 0.053 0.378 0.368 0.098 0.777 0.788 
rs6570507 6 142721265 2 GPR126 0.314 0.035 0.356 0.342 0.080 0.804 0.821 
rs11155242 6 142733242 2 GPR126 0.210 0.008 0.785 0.670 0.268 0.857 0.807 
rs7753012 6 142787576 2 GPR126 0.337 0.051 0.477 0.487 0.065 0.566 0.637 
rs3748069 6 142809326 2 GPR126 0.319 0.043 0.407 0.401 0.134 0.604 0.628 
rs171891 6 142892305 2,4 GPR126 0.198 0.013 0.884 0.741 0.129 0.830 0.815 
rs10512249 9 97296130 2 PTCH1 0.089 0.435 0.922 0.999 0.807 0.032 0.028 
rs11172113 12 55813550 5 LRP1 0.384 0.005 0.602 0.530 0.809 0.114 0.125 
rs1036429 12 94795559 5 CCDC38 0.217 0.765 0.322 0.356 0.295 0.047 0.031 
rs2456526 15 50876734 1 ONECUT1 0.136 0.011 0.524 0.500 0.451 0.230 0.250 
rs12899618 15 69432174 3 THSD4 0.158 3.25E-04 0.253 0.390 0.328 0.596 0.668 
rs1913768 15 69436598 3,4 THSD4 0.159 4.78E-04 0.221 0.344 0.365 0.617 0.695 
rs2304488 16 56631711 1 MMP15 0.186 0.121 0.002 0.002 0.085 0.760 0.515 
rs12447804‡ 16 56632783 5 MMP15 0.179 0.121 0.003 0.003 0.085 0.719 0.487 
rs2865531‡ 16 73947817 5 CFDP1 0.428 0.035 0.621 0.736 0.377 0.840 0.603 
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